246 related articles for article (PubMed ID: 27863995)
1. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.
Huo M; Zhao Y; Satterlee AB; Wang Y; Xu Y; Huang L
J Control Release; 2017 Jan; 245():81-94. PubMed ID: 27863995
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.
Zhao Y; Huo M; Xu Z; Wang Y; Huang L
Biomaterials; 2015 Nov; 68():54-66. PubMed ID: 26264646
[TBL] [Abstract][Full Text] [Related]
4. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses.
Zeng Q; Jiang H; Wang T; Zhang Z; Gong T; Sun X
J Control Release; 2015 Feb; 200():1-12. PubMed ID: 25540903
[TBL] [Abstract][Full Text] [Related]
5. Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy.
Zhu H; Liu Q; Miao L; Musetti S; Huo M; Huang L
Nanoscale; 2020 Feb; 12(5):3400-3410. PubMed ID: 31989142
[TBL] [Abstract][Full Text] [Related]
6. Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model.
Lu Y; Miao L; Wang Y; Xu Z; Zhao Y; Shen Y; Xiang G; Huang L
Mol Ther; 2016 Feb; 24(2):364-374. PubMed ID: 26334519
[TBL] [Abstract][Full Text] [Related]
7. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.
Hou L; Liu Q; Shen L; Liu Y; Zhang X; Chen F; Huang L
Theranostics; 2018; 8(14):3781-3796. PubMed ID: 30083259
[No Abstract] [Full Text] [Related]
8. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF
J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699
[TBL] [Abstract][Full Text] [Related]
10. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
11. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach.
Juin SK; Ghosh S; Majumdar S
Int Immunopharmacol; 2020 Nov; 88():106932. PubMed ID: 32890791
[TBL] [Abstract][Full Text] [Related]
13. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA
Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518
[TBL] [Abstract][Full Text] [Related]
14. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model.
Silva JM; Zupancic E; Vandermeulen G; Oliveira VG; Salgado A; Videira M; Gaspar M; Graca L; Préat V; Florindo HF
J Control Release; 2015 Jan; 198():91-103. PubMed ID: 25483429
[TBL] [Abstract][Full Text] [Related]
15. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
17. Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Huang Q; Zhou C; Chen X; Dong B; Chen S; Zhang N; Liu Y; Li A; Yao M; Miao J; Li Q; Wang Z
PLoS One; 2015; 10(10):e0141395. PubMed ID: 26513662
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment.
Xu Z; Wang Y; Zhang L; Huang L
ACS Nano; 2014 Apr; 8(4):3636-45. PubMed ID: 24580381
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
Bose A; Taylor JL; Alber S; Watkins SC; Garcia JA; Rini BI; Ko JS; Cohen PA; Finke JH; Storkus WJ
Int J Cancer; 2011 Nov; 129(9):2158-70. PubMed ID: 21170961
[TBL] [Abstract][Full Text] [Related]
20. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
